[go: up one dir, main page]

WO2010026467A2 - Forme pharmaceutique à libération prolongée de principe actif hautement soluble - Google Patents

Forme pharmaceutique à libération prolongée de principe actif hautement soluble Download PDF

Info

Publication number
WO2010026467A2
WO2010026467A2 PCT/IB2009/006733 IB2009006733W WO2010026467A2 WO 2010026467 A2 WO2010026467 A2 WO 2010026467A2 IB 2009006733 W IB2009006733 W IB 2009006733W WO 2010026467 A2 WO2010026467 A2 WO 2010026467A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
tablet
active ingredient
release controlling
high solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/006733
Other languages
English (en)
Other versions
WO2010026467A3 (fr
Inventor
Jaya Abraham
Vinodkumar Gupta
Bhavesh Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of WO2010026467A2 publication Critical patent/WO2010026467A2/fr
Anticipated expiration legal-status Critical
Publication of WO2010026467A3 publication Critical patent/WO2010026467A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Definitions

  • the present invention relates to a solid oral controlled release tablet dosage form comprising high solubility active ingredient, wherein the dosage form is manufactured by single step granulation using atleast one hydrophobic release controlling agent and compressed tablet is coated with atleast one hydrophobic release controlling agent.
  • the present invention further discloses the process for preparing the said dosage form.
  • the blood level of the drug should be maintained within the therapeutic window.
  • Majority of drugs require multiple dosing in a day to maintain the desired therapeutic effect. Such multiple dosing is the main reason for the patient incompliance.
  • IR dosage forms are comprised of immediate release (IR) dosages in the form of tablets or capsules. These IR dosage forms release the active drug substance into the body of a subject at a rate that is initially very high followed by a rapid decline.
  • IR dosage form One potential result of an IR dosage form is that the subject may have high degree of blood level fluctuation, which may result in transient therapeutic overdose, followed by a period of therapeutic under dosing and which may some time lead to sub therapeutic blood levels and/or side effects to the patient.
  • a biphasic controlled release delivery system for metformin hydrochloride which has prolonged gastric residence and that swells following hydration.
  • the ratio of inner solid phase to outer continuous phase is 0.5: 1 to about 4: 1.
  • the major limitation of this invention is that it provides a very bulky formulation for higher doses of the metformin hydrochloride that is very inconvenient for human consumption.
  • example cited provides formulation of 500 mg metformin hydrochloride with tablet weight of about 1.0 gm.
  • the cited example teaches use of combination of atleast one hydrophilic polymer and which is an essential part for swelling. Non swellable or non erodeble formulations are not included in the invention.
  • US patent no. 6340475 B2 assigned to Depomed Inc. describes monolithic controlled release formulation of highly water soluble drugs including metformin hydrochloride.
  • the formulation swells when ingested thus prolonging its residence time in the stomach.
  • the formulations are made of hydrophilic polymers, which results in swellable and erodible matrix.
  • Chih-Ming Chen in international patent application number WO 02/36100 describes a once a day formulation of metformin hydrochloride which is based on osmotically controlled technique and that is non expandable in nature and has a passage in the coating membrane for release of drug.
  • Kim et al. in United States patent number 6337091 describes a matrix based controlled release formulation for highly soluble drugs over long periods of time.
  • the release controlling agent is a swellable gum which encapsulates or make granules of drug, which is then disposed in more swellable erodible polymers such as HPMC or poly (ethyleneoxide).
  • CN 1628690 discloses a citicoline sustained and controlled release preparation prepared by matrix system using HPMC as release controlling agent and other conventional adjuvant and process for making the same. The amount of polymer required here almost more than 100% of the amount of citicoline which results in unacceptable size of the dosage form.
  • micromatrix particles comprises active ingredient and release controlling agent and said micromatrix particles are further coated with release controlling agent. These coated micromatrix particles are then compressed into tablets.
  • WO/2006080029 discloses an extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it.
  • the extended release tablet of Levetiracetam with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer.
  • atleast 45% release controlling polymer is required with respect the active substance to achieve the desired dissolution profile; which results in unacceptable size of the dosage form.
  • WO/2006123357 discloses oral controlled release pharmaceutical composition
  • a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam and a rate controlling means comprising a rate-controlling agent and optionally coating selected form (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form.
  • a rate controlling means comprising a rate-controlling agent and optionally coating selected form (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form.
  • WO/2008006528 discloses controlled release pharmaceutical composition in the form of a tablet comprising, levetiracetam and, as excipient within the core of the tablet, 5.0 to 59.0 % per weight of at least one hydrophilic matrix agent, with respect to the total weight of the core of the tablet.
  • WO/2008/062446 discloses an extended release composition of Levetiracetam, which exhibits no adverse food effect, comprising from about 30% w/w to about 85% w/w of Levetiracetam and about 1 % w/w to about 50% w/w of the composition of a water dispersible rate controlling polymer.
  • the first embodiment of the present invention is to provide solid oral controlled release tablet dosage form comprising high solubility active ingredient.
  • Another embodiment of the present invention is to provide solid oral controlled release tablet dosage form comprising high solubility active ingredient, wherein the dosage form is manufactured by single step granulation using atleast one hydrophobic release controlling agent and compressed tablet is coated with atleast one hydrophobic release controlling agent.
  • Another embodiment of the present invention is to provide solid oral controlled release tablet dosage form comprising Levetiracetam, wherein the dosage form is manufactured by single step granulation using atleast one hydrophobic release controlling agent and compressed tablet is coated with atleast one hydrophobic release controlling agent.
  • Another embodiment of the present invention is to provide solid oral controlled release tablet dosage form comprising Citicoline, wherein the dosage form is manufactured by single step granulation using atleast one hydrophobic release controlling agent and compressed tablet is coated with atleast one hydrophobic release controlling agent.
  • Another embodiment of the present invention is to provide solid oral controlled release tablet dosage form comprising high solubility active ingredient manufactured by single step granulation using atleast one hydrophobic release controlling agent and compressed tablet is coated with atleast one hydrophobic release controlling agent wherein the said dosage form is substantially devoid of diluent.
  • Another embodiment of the present invention is to provide solid oral controlled release tablet dosage form comprising high solubility active ingredient manufactured by single step granulation using atleast one hydrophobic release controlling agent and compressed tablet is coated with atleast one hydrophobic release controlling agent wherein the said dosage form is devoid of diluent.
  • Yet another embodiment of the present invention is to provide a dosage form which controls the release of high solubility active ingredient from the dosage form in a controlled rate and avoid the risk of side effects due to dose dumping because of breakage of the dosage form.
  • a further embodiment of the present invention is to provide a dosage form, which can be given once or twice daily.
  • Another embodiment of present invention is to provide process for preparing the controlled release dosage form of high solubility active ingredient.
  • Yet another embodiment of the present invention is to provide a method of treating an mammal, particularly a human being in need of treatment, comprising administering a said dosage form.
  • the present invention provides a controlled release dosage form, which comprises of: a) granules comprising high solubility active ingredient and one or more hydrophobic release controlling agent; b) tablet prepared by compressing the granule(s) of step a) with one or more pharmaceutically acceptable excipients; and c) coating of one or more hydrophobic release controlling agent on said tablets.
  • the present invention using the hydrophobic release controlling agent within the granule(s) and over the tablet as a coating, effectively controls the release of the high solubility active ingredient from the dosage form in controlled manner and also avoid the risk of failure of the system due to rupture of matrix.
  • controlled release means which is not immediate release and is taken to encompass modified release, sustained release, prolonged release, timed release, retarded release, extended release, and delayed release, etc. in which the active ingredient is released according to a desired profile over an extended period of time.
  • extended period of time it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours.
  • dosage form denotes any form of the formulation that contains an amount sufficient to produce a therapeutic effect with a single administration.
  • the dosage form used herein is for oral administration.
  • the preferred oral dosage forms are selected from granule, powder, pills, pellets, and more preferred dosage form is tablet.
  • active ingredient refers to an agent, active ingredient compound or other substance, or compositions and mixture thereof that provide some pharmacological, often beneficial, effect. Reference to a specific active ingredient shall include where appropriate the active ingredient and it's pharmaceutically acceptable salts.
  • high dose refers to the weight of active ingredient in unit dosage form according to the invention is from 500 mg to 1500 mg.
  • high solubility as used herein in relation to active ingredient means that 300 parts of water, preferably 30 parts of water, more preferably 10 parts of water will be required to dissolve 1 part of active ingredient.
  • the high solubility active ingredient can be present in the form of a free base or in the form of pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts forming part of this invention are intended to define but not limited to salts of the carboxylic acid moiety such as alkali metal salts like Li, Na and K salts; alkaline earth metal salts like Ca and Mg salts; salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, and the like; ammonium or substituted ammonium salts and aluminium salts.
  • Salts may be acid addition salts which defines but not limited to sulfates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzensulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
  • high solubility active ingredient may be present either in the form of one substantially optically pure enantiomer or as a mixture of enantiomers or polymorphs thereof.
  • the high solubility active ingredients comprises of the following therapeutic classes but not limited to antidiabetics such as biguanides, sulphonylurea, meglitinides, PPAR gamma agonist [insulin sensitisers (thiazolidinedione)] and alpha-glucosidase inhibitors; antiobesity drugs; cardiovascular agents such as diuretics, antihypertensives, antianginals, antithrombotics, anti-cholesterolemics, and antihyperlipidemics; CNS agents such as antipsychotics, neuroleptics, anticonvulsants, anti-depressants, anxiolytic agents, antiparkinsons, cerebral dilators and antialzheimers; anti-viral agents; anesthetics; anti-arthritis; antibiotics; anti-spasmodics; appetite suppressants; cough suppressants; emollients; gastro-intestinal agents such as antiulcers and antacids; growth regulators; anti-hist
  • high solubility active ingredients comprises of but not limited to aminocaproic acid, acetaminophen, balsalazide disodium, buformin, clindamycin, captopril, citicoline, diltiazem, fexofenadine, erythromycin, hydroxyurea, lisinorpil, metformin, pseudoephedrine, phenformin, potassium chloride, ranitidine, tramadol, vancomycin, ciprofloxacin, ampicillin, sodium valproate, niacin, diltiazem, venlafaxine, isosorbide 5-imononitrate, isosorbide dinitrate, pentoxyphylline, levetiracetam, paliperidone, methyl phenidate, propranolol and quetiapine.
  • granule(s) as used herein means individual particles, beads, pellets or agglomerates of individual particles of the high solubility active ingredient with one or more pharmaceutically acceptable excipients.
  • Granule(s) as used herein can be manufactured by any known method to the person skilled in the art like wet granulation, dry granulation, melt granulation, extrusion, spheronization or by roller compaction and the like.
  • Preferred method for granulation is wet granulation using aqueous or non aqueous solvent. More preferably the granulation method is non aqueous wet granulation.
  • single step granulation means wet granulation, dry granulation including direct compression, melt granulation, extrusion, spheronization or by roller compaction wherein high solubility active ingredient and atleast one pharmaceutically acceptable ingredient are granulated once by above mentioned process.
  • Compression of granules to the tablet as used herein can be done on usual compression machines.
  • the tablets can be made of various sizes and shapes.
  • Coating of the tablet as used herein can be done with one or more hydrophobic release controlling agents by any known method, including spray application. Spraying can be carried out using a fluidized bed coating, or in a pan coating system. Alternatively the coating of the tablets with one or more hydrophobic release controlling agents can be done by hot melt process using fluidized bed coating, or in a pan coating system.
  • a dosage form of the present invention may contain additionally one or more active ingredient.
  • a dosage form as described herein may comprise one or more pharmaceutically acceptable excipient, during granulation, compression or coating, selected from diluent/filler, glidants, disintegrant, binder, stabilizing agents, lubricant, hydrophobic release controlling agent, plasticizers, film coating agents, opacifiers, stabilizers, anti- tacking agent, and others known to the skilled person in the art.
  • excipient selected from diluent/filler, glidants, disintegrant, binder, stabilizing agents, lubricant, hydrophobic release controlling agent, plasticizers, film coating agents, opacifiers, stabilizers, anti- tacking agent, and others known to the skilled person in the art.
  • excipient during granulation, compression or coating, selected from diluent/filler, glidants, disintegrant, binder, stabilizing agents, lubricant, hydrophobic release controlling agent, plasticizers, film coating agents, opacifiers, stabilizers, anti-
  • diluents or “fillers” includes but not limited to dibasic calcium phosphate, lactose anhydrous, lactose monohydrate, pregelatinized starch, mannitol, microcrystalline cellulose, powdered cellulose, sorbitol, starch or other materials known to one of ordinary skill in the art.
  • the diluent may be present in an amount ranging from 0% to 50 % w/w by total weight of dosage form.
  • substantially devoid of diluent as used herein means that the dosage form comprising less than 5% w/w of diluent by total weight of dosage form.
  • binder includes but not limited to polyvinylpyrrolidone, hypromellose, hydroxy methylcellulose, PEG, starch, copovidone, shellac, zein, gelatin, polymethacrylates, synthetic resins, acrylates or other materials known to one of ordinary skill in the art.
  • glidant includes but not limited to colloidal silica, talc, calcium silicate, magnesium silicate, colloidal silicondioxide or other known to one of ordinary skill in the art.
  • lubricant includes but not limited to Stearic acid, Polyethylene glycol, Magnesium stearate, Calcium stearate, Zinc stearate, Talc or Silica, Glyceryl behenate, Sodium stearyl fumarate, Hydrogenated caster oil or other materials known to one of ordinary skill in the art.
  • 'plasticizer' includes but not limited to Triethyl citrate, PEG 6000, Glyceryl monopalmetostearate / Glyceryl monostearate, Dibutyl phthalate, Macrogol or other materials known to one of ordinary skill in the art.
  • opacifier examples include but not limited to titanium dioxide or talc.
  • solvents used to prepare solution of release controlling agent for the granulation or coating includes but not limited to aqueous or organic solvent preferably organic solvent and more preferably Methanol, Methylene chloride, Acetone, Isopropyl alcohol or combination thereof.
  • excipients that can be used as the hydrophobic release controlling agent within the granule(s) and over the tablet as coating are described in greater detail herein below.
  • hydrophobic release controlling agents as used herein in the granulation or coating are selected from hydrophobic, pH independent release controlling agents and / or hydrophobic, pH dependent release controlling agents, more preferably hydrophobic, pH independent release controlling agents.
  • Preferable hydrophobic, pH independent release controlling agent is selected from Ammonio methacrylate copolymers type A and B as described in USP, Polyacrylate dispersion 30% as described in Ph. Eur., Cellulose derivatives, Kollicoat” SR, Kollicoat ® SR 30 D (polyvinyl acetate dispersion stabilised with polyvinylpyrrolidone and sodium lauryl sulphate) or combination thereof.
  • the hydrophobic release controlling agents may be added at intragranular stage, extragranular stage, binder addition stage and tablet coating stage.
  • the suitable hydrophobic release controlling agents are sold under the Trade name Eudragit® RS (Ammonio Methacrylate Copolymer type B USP), Eudragit® NE 3OD (Polyacrylate dispersion 30% Ph., Eur.), Eudragit® RL (Ammonio Methacrylate Copolymer type A USP), Kollicoat ® SR 30 D (polyvinyl acetate dispersion stabilised with polyvinylpyrrolidone and sodium lauryl sulphate).
  • Preferred release controlling agent for granulation is Eudragit® RS and for coating of tablet is combination of two ammonio methacrylate co-polymers having different aqueous permeability or Kollicoat ® SR 30 D (polyvinyl acetate dispersion stabilised with polyvinylpyrrolidone and sodium lauryl sulphate).
  • More preferred combination of ammonio methacrylate co-polymer for tablet coating is Eudragit RS (Ammonio Methacrylate Copolymer type B USP) and Eudragit RL (Ammonio Methacrylate Copolymer type A USP).
  • the high solubility active ingredient and one or more hydrophobic release controlling agents are present in a weight ratio of from 100:1 to 100:75, preferably from 100:2.5 to 100:50, more preferably from 100:2.5 to 100:30 and still preferably from 100:2.5 to 100:20, most preferably from 100: 1 to 100:10.
  • the high solubility active ingredient and one or more hydrophobic, release controlling agents are preferably in a weight ratio of from 100: 0.1 to 100:30, particularly from 100:0.1 to 100:20, more particularly from 100:0.1 to 100:10, still more preferably from 100:0.25 to 100:10.
  • the controlled release dosage form of the present invention can be manufactured by the following procedure: a) granules comprising high solubility active ingredient and one or more hydrophobic release controlling agent; b) tablet prepared by compressing the granule(s) of step a) with one or more pharmaceutically acceptable excipients; and c) coating of one or more hydrophobic release controlling agent on said tablets.
  • Example 1 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent.
  • the following detailed examples describe how to prepare the various dosage forms and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever:
  • Levetiracetam and Microcrystalline cellulose were mixed and granulated with the solution of Eudragit® RSPO in acetone and dried and sized. The sized granules were blended with Colloidal silicon dioxide and Glyceryl behenate. These lubricated granules were compressed using suitable tablet compression machine. The compressed tablets were coated with the coating solution of Eudragit® RSPO and Eudragit® RLPO in purified water with talc, titanium dioxide and Triethyl citrate. Dissolution data of Example 1
  • the dissolution of the present invention was determined by following method:
  • Levetiracetam and Microcrystalline cellulose were mixed and granulated with the solution of Eudragit® RSPO in acetone and dried and sized. The sized granules were blended with Colloidal silicondioxide and Glyceryl behenate. These lubricated granules were compressed using suitable tablet compression machine. The compressed tablets were coated with the coating solution of Kollicoat SR 30 D and HPMC (3 cps) in purified water with talc and Triethyl citrate. Dissolution data of Example 3
  • the dissolution of the present invention was determined by following method:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme pharmaceutique orale solide à libération prolongée comprenant un principe actif hautement soluble, la forme pharmaceutique étant fabriquée par granulation en une seule opération au moyen d'au moins un régulateur de libération hydrophobe. Cette forme pharmaceutique est en outre enrobée au moyen d'au moins un régulateur de libération hydrophobe. L'invention concerne également le procédé d'élaboration de ladite forme pharmaceutique.
PCT/IB2009/006733 2008-09-04 2009-09-03 Forme pharmaceutique à libération prolongée de principe actif hautement soluble Ceased WO2010026467A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1868MU2008 2008-09-04
IN1868/MUM/2008 2008-09-04

Publications (2)

Publication Number Publication Date
WO2010026467A2 true WO2010026467A2 (fr) 2010-03-11
WO2010026467A3 WO2010026467A3 (fr) 2011-06-03

Family

ID=41797589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006733 Ceased WO2010026467A2 (fr) 2008-09-04 2009-09-03 Forme pharmaceutique à libération prolongée de principe actif hautement soluble

Country Status (1)

Country Link
WO (1) WO2010026467A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277511A1 (fr) * 2009-07-22 2011-01-26 Sanovel Ilac Sanayi ve Ticaret A.S. Composition pharmaceutique de levetiracetam à libération prolongée
WO2011159491A3 (fr) * 2010-06-16 2012-06-28 Mylan Inc. Formulations de lévétiracétam à libération contrôlée
CN102688214A (zh) * 2012-06-15 2012-09-26 孙威 一种左乙拉西坦缓释片制备方法
CN103191079A (zh) * 2013-04-01 2013-07-10 济南利民制药有限责任公司 一种胞磷胆碱钠片及其制备方法
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
EP2882292A4 (fr) * 2012-08-08 2016-04-06 Pharmtak Inc Lévétiracétam à libération prolongée et procédé de préparation
US20180228798A1 (en) * 2015-08-08 2018-08-16 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
US10143659B2 (en) * 2012-12-31 2018-12-04 Samyang Biopharmaceutical Corporation Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026718A2 (fr) 1995-02-28 1996-09-06 Temple University Of The Commonwealth System Of Higher Education Comprime a liberation controlee
WO1999047128A1 (fr) 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US6340475B2 (en) 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO2002036100A1 (fr) 2000-11-03 2002-05-10 Andrx Corporation Compositions de metformine a liberation controlee
CN1628690A (zh) 2003-12-15 2005-06-22 孟繁浩 胞磷胆碱缓控释制剂及其制备方法
WO2006080029A1 (fr) 2005-01-27 2006-08-03 Alembic Limited Formulation de lévétiracétam à libération prolongée
WO2006123357A2 (fr) 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Composition pharmaceutique
WO2008006528A2 (fr) 2006-07-13 2008-01-17 Ucb Pharma, S.A. Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
WO2008062446A2 (fr) 2006-09-14 2008-05-29 Alembic Limited Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
ID28783A (id) * 1998-11-12 2001-07-05 Smithkline Beecham Plc Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain
HK1042427A1 (zh) * 1999-09-30 2002-08-16 Penwest Pharmaceuticals Co. 用於高溶度药物的持续释放基质方法
GB0117619D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
EA200800162A1 (ru) * 2005-06-29 2008-06-30 Панацея Биотек Лтд. Новые фармацевтические композиции с замедленным высвобождением и способы их получения
FR2912056B1 (fr) * 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026718A2 (fr) 1995-02-28 1996-09-06 Temple University Of The Commonwealth System Of Higher Education Comprime a liberation controlee
US6340475B2 (en) 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
WO1999047128A1 (fr) 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
WO2002036100A1 (fr) 2000-11-03 2002-05-10 Andrx Corporation Compositions de metformine a liberation controlee
CN1628690A (zh) 2003-12-15 2005-06-22 孟繁浩 胞磷胆碱缓控释制剂及其制备方法
WO2006080029A1 (fr) 2005-01-27 2006-08-03 Alembic Limited Formulation de lévétiracétam à libération prolongée
WO2006123357A2 (fr) 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Composition pharmaceutique
WO2008006528A2 (fr) 2006-07-13 2008-01-17 Ucb Pharma, S.A. Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
WO2008062446A2 (fr) 2006-09-14 2008-05-29 Alembic Limited Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
EP2277511A1 (fr) * 2009-07-22 2011-01-26 Sanovel Ilac Sanayi ve Ticaret A.S. Composition pharmaceutique de levetiracetam à libération prolongée
CN102970980A (zh) * 2010-06-16 2013-03-13 迈兰公司 控制释放的左乙拉西坦配方
WO2011159491A3 (fr) * 2010-06-16 2012-06-28 Mylan Inc. Formulations de lévétiracétam à libération contrôlée
US9333175B2 (en) 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
CN102688214A (zh) * 2012-06-15 2012-09-26 孙威 一种左乙拉西坦缓释片制备方法
CN102688214B (zh) * 2012-06-15 2013-05-22 孙威 一种左乙拉西坦缓释片制备方法
EP2882292A4 (fr) * 2012-08-08 2016-04-06 Pharmtak Inc Lévétiracétam à libération prolongée et procédé de préparation
US10143659B2 (en) * 2012-12-31 2018-12-04 Samyang Biopharmaceutical Corporation Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same
CN103191079A (zh) * 2013-04-01 2013-07-10 济南利民制药有限责任公司 一种胞磷胆碱钠片及其制备方法
US20180228798A1 (en) * 2015-08-08 2018-08-16 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
US11058682B2 (en) * 2015-08-08 2021-07-13 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
US11590127B2 (en) 2015-08-08 2023-02-28 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole

Also Published As

Publication number Publication date
WO2010026467A3 (fr) 2011-06-03

Similar Documents

Publication Publication Date Title
US8216609B2 (en) Modified release composition of highly soluble drugs
AU2019278013B2 (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation methods and uses thereof
US8323692B2 (en) Controlled release dosage forms
CN102895208B (zh) 包衣片制剂和方法
US7427414B2 (en) Modified release oral dosage form using co-polymer of polyvinyl acetate
US20110217374A1 (en) pharmaceutical composition simultaneously having rapid-acting property and long-acting property
KR101317592B1 (ko) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
WO2010026467A2 (fr) Forme pharmaceutique à libération prolongée de principe actif hautement soluble
WO2005048979A2 (fr) Composition pharmaceutique avec capsule pour microtablettes multiples
EP2187874A2 (fr) Compositions à libération prolongée de trimétazidine et procédé de préparation
US8440223B2 (en) Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers
EP0951278A2 (fr) Formulation de minicomprimes de cisapride a liberation prolongee
KR20060120596A (ko) 로피니롤의 신규 제형
US20120003307A1 (en) Levetiracetam controlled release composition
EP2468268B1 (fr) Composition de combinaison de vildagliptine et de gliclazide
US20070122480A1 (en) Sustained release formulations
EP2726064A1 (fr) Forme posologique orale à libération contrôlée comprenant de l'oxycodone
KR20170061219A (ko) 방출제어형 경질캡슐 제제
KR100591142B1 (ko) 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
EP3796908B1 (fr) Formulations de propivérine à libération contrôlée
US20150250734A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2024165966A1 (fr) Compositions de riociguat à libération prolongée et à rétention gastrique
AU2006252394A1 (en) Modified-release composition of at least one form of venlafaxine
US11147767B2 (en) Gastroretentive formulations
US20080081069A1 (en) Novel controlled release formulations of divalproex sodium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09771407

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 09771407

Country of ref document: EP

Kind code of ref document: A2